Lonza AG

Ethris and Lonza to Develop Spray-Dried mRNA Respiratory Vaccines

Ethris and Lonza have teamed up to develop room-temperature stable, spray-dried mRNA vaccines for respiratory diseases. This collaboration aims to create mucosal delivery formulations, offering a promising new approach to combat respiratory illnesses.

Lonza Outlines Restructuring Strategy and New Organizational Structure

At an investor update at the end of last week, Lonza has announced its "One Lonza" restructuring strategy, which aims to reorganize its CDMO business, simplify its operating model, enhance manufacturing and engineering, and expand its production footprint.

Lonza to Expand Bioconjugation in Visp, Switzerland

Lonza, a global contract development and manufacturing organization (CDMO) for the pharmaceutical, biotech, and nutraceutical markets, announced today that it will invest in additional bioconjugation capabilities in Visp, Switzerland.

Lonza Extends ADC Manufacturing Collaboration with Biopharma Company

Swiss contract development and manufacturing organization (CDMO) Lonza has announced a long-term extension of its collaboration with a key global biopharmaceutical partner for the manufacture of antibody-drug conjugates (ADCs) at commercial scale. The name of the partner was not disclosed.

Lonza Completes Acquisition of Vacaville Biologics Site from Roche

Lonza has completed its acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California, USA, from Roche for $1.2 billion. The deal was announced in March of this year.

Lonza and Vertex Sign a Commercial Supply Agreement for Casgevy

Lonza and Vertex Pharmaceuticals recently announced a commercial supply agreement for casgevy (exagamglogene autotemcel).

Lonza Launches Innovaform Accelerator

Lonza inaugurated its new facility at the Colmar, France site. The new Innovaform Accelerator will serve as a Center of Excellence for developing and innovating capsule-based manufacturing and delivery solutions for oral and pulmonary administration.

​​Lonza Completes Expansion of Microbial Manufacturing Facility

Lonza recently announced that it has completed a planned expansion of the mid-scale microbial manufacturing facility at its Visp, Switzerland site. This multi-product facility was recently granted a GMP license, allowing cGMP manufacturing and release of biologics produced using microbial fermentation.

Large-Scale Production Announced by Epsilogen and Lonza for Ovarian Cancer Treatment

Epsilogen and Lonza have successfully completed the manufacturing of a potential cancer treatment. The complex process, which took less than ten months, was carried out at Lonza’s UK site following Good Manufacturing Practice (GMP) standards.

Lonza Announces New Mid-Term Guidance 2024 – 2028

At its Capital Markets Day in Visp, Switzerland, Lonza shared a detailed update on its strategic priorities and provided new Mid-Term Guidance for 2024 to 2028.

Spray Drying for Inhalation: the Challenges of Scale-up

When developing an inhaled powder formulation, the drug particles’ properties are critical to successful delivery to the deep lung. The aerodynamic diameter is the key parameter, as it represents how well the particle flies in an air stream.

Lonza Increases Capacity for Antibody-Drug Conjugates at Visp, Switzerland

Swiss contract development and manufacturing organization (CDMO) Lonza is extending a long-term collaboration with an unnamed major global biopharmaceutical partner. Under the agreement, the current dedicated bioconjugation capacity will be increased fourfold by adding two new bioconjugation suites for the commercial supply of antibody-drug conjugates (ADCs) at Lonza's site in Visp, Switzerland.

Integrated Drug Development Models

Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.

The Rise of HPAPI Molecules

For biopharma leaders it is more critical than ever to secure the capabilities to contain, handle, develop and manufacture highly potent APIs.

Lonza’s Corporate Overhaul

Lonza To Build Formulation Plant in Visp

Lonza to Buy Arch Chemicals for $1.2 Billion

Lonza Expects Solid Growth in 2011, 2010 Net Up 79%

Lonza Shares Fall After Deutsche Bank Downgrade

Stefan Borgas: Strong Franc Major Challenge for Swiss Economy

H1 2010: Lonza Reports Improved Order Placement and Contract Signing

Adapting For Survival